These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 26816081

  • 1. D-SAL and NAP: Two Peptides Sharing a SIP Domain.
    Gozes I, Sragovich S, Schirer Y, Idan-Feldman A.
    J Mol Neurosci; 2016 Jun; 59(2):220-31. PubMed ID: 26816081
    [Abstract] [Full Text] [Related]

  • 2. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
    Shiryaev N, Pikman R, Giladi E, Gozes I.
    Curr Pharm Des; 2011 Jun; 17(25):2603-12. PubMed ID: 21728979
    [Abstract] [Full Text] [Related]

  • 3. A Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP.
    Ivashko-Pachima Y, Gozes I.
    Front Cell Neurosci; 2019 Jun; 13():435. PubMed ID: 31632241
    [Abstract] [Full Text] [Related]

  • 4. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.
    Ivashko-Pachima Y, Sayas CL, Malishkevich A, Gozes I.
    Mol Psychiatry; 2017 Sep; 22(9):1335-1344. PubMed ID: 28115743
    [Abstract] [Full Text] [Related]

  • 5. The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins.
    Oz S, Kapitansky O, Ivashco-Pachima Y, Malishkevich A, Giladi E, Skalka N, Rosin-Arbesfeld R, Mittelman L, Segev O, Hirsch JA, Gozes I.
    Mol Psychiatry; 2014 Oct; 19(10):1115-24. PubMed ID: 25178163
    [Abstract] [Full Text] [Related]

  • 6. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).
    Gozes I, Divinski I, Piltzer I.
    BMC Neurosci; 2008 Dec 10; 9 Suppl 3(Suppl 3):S3. PubMed ID: 19091000
    [Abstract] [Full Text] [Related]

  • 7. Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy.
    Ivashko-Pachima Y, Gozes I.
    Prog Mol Biol Transl Sci; 2021 Dec 10; 177():65-90. PubMed ID: 33453943
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory.
    Amram N, Hacohen-Kleiman G, Sragovich S, Malishkevich A, Katz J, Touloumi O, Lagoudaki R, Grigoriadis NC, Giladi E, Yeheskel A, Pasmanik-Chor M, Jouroukhin Y, Gozes I.
    Mol Psychiatry; 2016 Oct 10; 21(10):1467-76. PubMed ID: 26782054
    [Abstract] [Full Text] [Related]

  • 10. Prevention of learning deficit in a Down syndrome model.
    Incerti M, Toso L, Vink J, Roberson R, Nold C, Abebe D, Spong CY.
    Obstet Gynecol; 2011 Feb 10; 117(2 Pt 1):354-361. PubMed ID: 21252750
    [Abstract] [Full Text] [Related]

  • 11. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model.
    Vaisburd S, Shemer Z, Yeheskel A, Giladi E, Gozes I.
    Sci Rep; 2015 Nov 10; 5():16300. PubMed ID: 26553741
    [Abstract] [Full Text] [Related]

  • 12. VIP/PACAP-Based Drug Development: The ADNP/NAP-Derived Mirror Peptides SKIP and D-SKIP Exhibit Distinctive in vivo and in silico Effects.
    Sragovich S, Amram N, Yeheskel A, Gozes I.
    Front Cell Neurosci; 2019 Nov 10; 13():589. PubMed ID: 31992971
    [Abstract] [Full Text] [Related]

  • 13. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze.
    Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE.
    J Pharmacol Exp Ther; 2000 Jun 10; 293(3):1091-8. PubMed ID: 10869414
    [Abstract] [Full Text] [Related]

  • 14. Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL.
    Holtser-Cochav M, Divinski I, Gozes I.
    J Mol Neurosci; 2006 Jun 10; 28(3):303-7. PubMed ID: 16691018
    [Abstract] [Full Text] [Related]

  • 15. Prenatal NAP+SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and gamma-aminobutyric acid receptors.
    Vink J, Incerti M, Toso L, Roberson R, Abebe D, Spong CY.
    Am J Obstet Gynecol; 2009 May 10; 200(5):524.e1-4. PubMed ID: 19327737
    [Abstract] [Full Text] [Related]

  • 16. Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures.
    Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR, Plata-Salaman CR.
    J Mol Neurosci; 2005 May 10; 25(3):225-38. PubMed ID: 15800376
    [Abstract] [Full Text] [Related]

  • 17. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.
    Oz S, Ivashko-Pachima Y, Gozes I.
    PLoS One; 2012 May 10; 7(12):e51458. PubMed ID: 23272107
    [Abstract] [Full Text] [Related]

  • 18. Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein.
    Sari Y, Gozes I.
    Brain Res Rev; 2006 Aug 30; 52(1):107-18. PubMed ID: 16488478
    [Abstract] [Full Text] [Related]

  • 19. Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model.
    Idan-Feldman A, Schirer Y, Polyzoidou E, Touloumi O, Lagoudaki R, Grigoriadis NC, Gozes I.
    Neurobiol Dis; 2011 Dec 30; 44(3):327-39. PubMed ID: 21827858
    [Abstract] [Full Text] [Related]

  • 20. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).
    Magen I, Gozes I.
    Neuropeptides; 2013 Dec 30; 47(6):489-95. PubMed ID: 24210139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.